PriceTargets.com logo

Allakos - ALLK Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.33 As of 05/15/2025 01:00 AM ET
+0 (0.00%)
Get New Allakos Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALLK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALLK

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Allakos in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.33.

This chart shows the closing price for ALLK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Allakos. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
9/2/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2026

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/27/2025Piper SandlerDowngradeStrong-Buy ➝ Hold
1/27/2025Citizens JmpDowngradeStrong-Buy ➝ Hold
9/26/2024Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$3.00 ➝ $3.00
7/18/2024Jefferies Financial GroupLower TargetHold ➝ Hold$1.50 ➝ $1.00
6/26/2024Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$3.00 ➝ $3.00
6/20/2024Cantor FitzgeraldReiterated RatingNeutral
1/17/2024Citizens JmpLower TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $3.00
1/17/2024BarclaysLower TargetUnderweight ➝ Underweight$1.50 ➝ $1.00
1/17/2024Jefferies Financial GroupDowngradeBuy ➝ Hold$6.00 ➝ $1.50
1/16/2024Cantor FitzgeraldDowngradeOverweight ➝ Neutral
12/18/2023William BlairUpgradeMarket Perform ➝ Outperform
12/8/2023Jefferies Financial GroupReiterated RatingBuy$9.00 ➝ $6.00
11/28/2023Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$10.00
11/14/2023Citizens JmpLower TargetMarket Outperform ➝ Market Outperform$11.00 ➝ $10.00
11/14/2023BarclaysLower TargetUnderweight ➝ Underweight$2.50 ➝ $1.50
9/27/2023Citizens JmpInitiated CoverageOutperform$11.00
5/11/2023Jefferies Financial GroupUpgradeHold ➝ Buy$6.00 ➝ $9.00
3/7/2023Cantor FitzgeraldReiterated RatingOverweight$7.00
3/7/2023Piper SandlerInitiated CoverageOverweight
2/27/2023Cantor FitzgeraldReiterated RatingOverweight$7.00
1/27/2023Morgan StanleyBoost TargetEqual Weight$6.00 ➝ $8.00
9/12/2022Sumitomo Mitsui Financial GroupDowngradeNeutral ➝ Underperform
5/9/2022Cantor FitzgeraldReiterated RatingOverweight
2/16/2022Leerink PartnersLower TargetMarket Perform$17.00 ➝ $13.00
12/28/2021HC WainwrightLower TargetBuy$230.00 ➝ $20.00
12/23/2021The Goldman Sachs GroupLower TargetNeutral$122.00 ➝ $60.00
12/22/2021Lifesci CapitalDowngradeOutperform ➝ Market Perform
12/22/2021Bank of AmericaDowngradeBuy ➝ Underperform
12/22/2021Jefferies Financial GroupDowngradeBuy ➝ Hold
12/22/2021TD CowenDowngradeOutperform ➝ Market Perform
12/22/2021Leerink PartnersDowngradeOutperform ➝ Market Perform$150.00 ➝ $17.00
12/22/2021William BlairDowngradeOutperform ➝ Market Perform
12/13/2021Bank of AmericaBoost TargetBuy$145.00 ➝ $155.00
11/10/2021Morgan StanleyLower TargetEqual Weight$88.00 ➝ $86.00
10/18/2021Cantor FitzgeraldReiterated RatingOverweight
8/26/2021Morgan StanleyInitiated CoverageEqual Weight$88.00
7/15/2021TD CowenInitiated CoverageOutperform$76.53
5/18/2021HC WainwrightInitiated CoverageBuy$230.00
2/24/2021Cantor FitzgeraldInitiated CoverageOverweight$218.00
(Data available from 2/24/2021 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2026

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Allakos logo
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $0.33
Low: $0.33
High: $0.33

50 Day Range

MA: $0.33
Low: $0.33
High: $0.33

52 Week Range

Now: $0.33
Low: $0.22
High: $1.56

Volume

N/A

Average Volume

1,250,862 shs

Market Capitalization

$29.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Allakos?

The following equities research analysts have issued stock ratings on Allakos in the last year:
View the latest analyst ratings for ALLK.

What is the current price target for Allakos?

0 Wall Street analysts have set twelve-month price targets for Allakos in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Allakos in the next year.
View the latest price targets for ALLK.

What is the current consensus analyst rating for Allakos?

Allakos currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ALLK.

What other companies compete with Allakos?

Other companies that are similar to Allakos include Cassava Sciences, Equillium, Cardiff Oncology, Repare Therapeutics and JATT Acquisition. Learn More about companies similar to Allakos.

How do I contact Allakos' investor relations team?

Allakos' physical mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company's listed phone number is (650) 597-5002 and its investor relations email address is [email protected]. The official website for Allakos is www.allakos.com. Learn More about contacing Allakos investor relations.